New Approaches to Neuroblastoma Therapy (NANT)
New Therapy, New Hope
Our vision is to cure all children with high-risk neuroblastoma using novel precision therapies developed by our expert network of laboratory and clinical investigators.
News
The "STING" trial (Sequential Temozolomide, Irinotecan, NK cells and GD2 mAb)
is now open to patient enrollment
Chemoimmunotherapy with dinutuximab, temozolomide, irinotecan and GM-CSF has been shown to be active against high-risk neuroblastoma that has returned or not responded to treatment. The STING study is trying to learn if this treatment can work better by adding Natural Killer (NK) cells. NK cells use the body's own immune system to kill neuroblastoma cells. However NK cells are only present in the body in small numbers and don't work very well against tumor because neuroblastoma releases chemicals (incdluing TGF-beta) that weaken the NK cells.
The STING trial uses a newer process to make specially chosen donated NK cells which may work better than the patient's own NK cells (called TGF-beta imprinted NK cells). These donor NK cells may be better killers of neuroblastoma tumor cells because they were exposed to TFG-beta while they are being prepared and grown in numbers in a laboratory. These special NK cells have been collected from donors and stored for use. They will be given to patients after the chemoimmunotherapy infusion is completed.
For more information on this trial, see the NANT 2021-01 page.
Currently Open Trials:
NANT Celebrated its first 20 years of accomplishments in 2020
You can hear NANT investigators presenting NANT’s accomplishments in its first 20 years, current NANT trials, and successor trials in the Children’s Oncology Group based on NANT trial data. This lecture was presented via the Coalition Against Childhood Cancer (CAC2) in 2020.